Reversal of the Antithrombotic Action of New Oral Anticoagulants (REVANT)
|ClinicalTrials.gov Identifier: NCT01478282|
Recruitment Status : Unknown
Verified March 2012 by Gines Escolar, Fundació Clínic per la Recerca Biomèdica.
Recruitment status was: Recruiting
First Posted : November 23, 2011
Last Update Posted : March 12, 2012
Ministry of Health, Spain
Information provided by (Responsible Party):
Gines Escolar, Fundació Clínic per la Recerca Biomèdica
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||December 2012|
|Submission Cycle||Results Submitted to ClinicalTrials.gov||Results Returned after Quality Control Review|
|1||March 23, 2015||March 31, 2015|
|2||August 11, 2015||September 11, 2015|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Arellano-Rodrigo E, Lopez-Vilchez I, Galan AM, Molina P, Reverter JC, Carné X, Villalta J, Tassies D, Lozano M, Díaz-Ricart M, Escolar G. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers. Transfus Med Rev. 2015 Oct;29(4):242-9. doi: 10.1016/j.tmrv.2015.08.001. Epub 2015 Aug 8.